Research Projects Page

Prior to the release of sofosbuvir/velpatasvir/voxilaprevir, few options for retreating patients failing HCV direct acting antiviral (DAA) therapy. This study evaluated the effectiveness of sofosbuvir + simeprevir + ribavirin for 24 weeks in retreating patients who previously failed HCV treatment containing an NS5A inhibitor.

This study demonstrated the benefits of pharmacist integration into an interdisciplinary to treatment patients with chronic HCV. Pharmacist integration resulted in improved patient engagement, reduced provider burden, and increased rate of HCV treatment.

While historical treatments combining interferon and ribavirin were less efficacious in HIV/HCV coinfection, modern direct-acting antiviral (DAA) therapies have shown similar clinical efficacy in HIV/HCV coinfection as in HCV monoinfection. In light of these findings, HIV/HCVcoinfected patients may benefit even more from new HCV treatment approaches. This article reviews the many therapeutic options for HIV/HCV coinfected patients with emphasis on avoiding drug-drug interactions.

This study was among the first to evaluate patient outcomes to all-oral, sofosbuvir (SOF)-based, HCV therapies in a real world setting and assess the impact of a clinic-integrated specialty pharmacy on therapy completion. We found higher completion rates in patients filling through VSP (97%) compared to outside pharmacies (93%), and a 100% medication access rate.